Table 3.

Non-inferiority comparison of H. pylori eradication rates between the VD and VBQ groups.

Analysis set	VBQ	VD	P-value for superiority	P-value for non-inferiority	Risk difference*
ITT	83.4% (161/193) (95% CI: 78.2%, 88.7%)	79.3% (153/193) (95% CI: 73.6%, 85.0%)	0.296	0.070	-4.15% (95% CI: -11.91%, 3.61%)
mITT	90.4% (161/178) (95% CI: 86.1%, 94.8%)	87.4% (153/175) (95% CI: 82.5%, 92.3%)	0.365	0.018	-3.02% (95% CI: -9.56%, 3.52%)
PP	90.1% (155/172) (95% CI: 85.7%, 94.6%)	87.7% (150/171) (95% CI: 82.8%, 92.6%)	0.479	0.012	-2.40% (95% CI: -9.04%, 4.24%)

*Risk difference calculated as VD group minus VBQ group. The prespecified non-inferiority margin was -10%. Non-inferiority is concluded if the lower limit of the 95% confidence interval for the risk difference is above -10%.

H. pylori, Helicobacter pylori; VBQ, vonoprazan-bismuth-amoxicillin-doxycycline quadruple therapy; VD, vonoprazan-doxycycline dual therapy; ITT, intention-to-treat; mITT, modified intention-to-treat; PP, per-protocol.